Commentary

Vol. 7, No. 3; 2023; pp 79–80
DOI: https://doi.org/10.26676/jevtm.19507

Enhancing Oxygen Uptake in Hypovolemic Shock: Exploring the Role of Oxygen-Increasing Drugs

Kessel–Khan Corner

Mansoor Khan[1] and Boris Kessel[2]

[1]*Department of Trauma Surgery, Hull Royal Infirmary, Hull, UK*
[2]*Division of General Surgery and Trauma, Hillel Yaffe Medical Center, affiliated with Rappaport Medical School, Technion, Haifa, Israel*

Received: 23 December 2023; Accepted: 27 December 2023

INTRODUCTION

Hypovolemic shock is a life-threatening condition characterized by a severe loss of blood volume, resulting in inadequate tissue perfusion and oxygenation. Prompt intervention is crucial to restore perfusion and prevent organ damage. In recent years, researchers have explored the potential of using drugs to increase oxygen uptake in end organs during hypovolemic shock. These medications aim to enhance tissue oxygenation, promote cellular function, and improve overall patient outcomes. In our corner, we will delve into some of the drugs being investigated and their potential impact on hypovolemic shock management.

The Importance of Oxygen Uptake in Hypovolemic Shock

Before we dive into the drugs that can potentially increase oxygen uptake, let us briefly understand why it is essential. In hypovolemic shock, reduced blood volume leads to diminished oxygen delivery to the tissues. Oxygen uptake refers to the process by which tissues extract and utilize oxygen for cellular respiration. Adequate oxygen uptake is vital for maintaining cellular metabolism and preventing cellular injury or death.

Corresponding author:
Mansoor Khan, Department of Trauma Surgery, Hull Royal Infirmary, Hull, UK.
Email: manskhan@doctors.org.uk

© 2024 The Author(s)
This is an open access article published under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Enhancing Oxygen Uptake: Exploring Drug Options

(1) *Vasopressors and inotropes:* Vasopressors and inotropes are commonly used in the management of hypovolemic shock. These medications work by increasing blood pressure and cardiac output, which in turn enhances tissue perfusion and oxygen delivery. By restoring blood flow to vital organs, these drugs indirectly facilitate oxygen uptake in end organs.

(2) *Oxygen therapies:* Supplemental oxygen is a fundamental intervention in managing hypovolemic shock. It provides a higher concentration of oxygen to the patient, increasing the oxygen-carrying capacity of the blood. Administering oxygen via various methods, such as nasal cannulas or face masks, can effectively improve tissue oxygenation [1].

(3) *Hyperbaric oxygen therapy:* Hyperbaric oxygen therapy involves exposing patients to pure oxygen at higher than atmospheric pressure levels. This therapy can enhance oxygen delivery to tissues, even in conditions where blood flow is compromised. While hyperbaric oxygen therapy may not directly increase blood volume, it promotes the dissolution of oxygen in plasma, facilitating oxygen uptake by end organs.

(4) *Perfluorocarbon emulsions:* Perfluorocarbon emulsions are synthetic compounds that can dissolve large amounts of oxygen and carbon dioxide [2,3]. When administered intravenously, these emulsions can temporarily increase the oxygen-carrying capacity of the blood, providing an alternative means of delivering oxygen to tissues. They have shown promise in experimental studies, but further research is needed to determine their clinical efficacy [4].

DISCUSSION

In the management of hypovolemic shock, the primary goal is to restore blood volume and improve tissue perfusion. While oxygen delivery can be enhanced through various interventions, increasing oxygen uptake in end organs remains a crucial aspect of patient care. Drugs such as vasopressors, inotropes, oxygen therapies, hyperbaric oxygen therapy, and perfluorocarbon emulsions hold the potential for optimizing tissue oxygenation and improving patient outcomes. However, it is important to note that the use of these drugs should be guided by medical professionals and further research is required to establish their efficacy and safety in the specific context of hypovolemic shock.

It is essential to emphasize that the management of hypovolemic shock requires a comprehensive approach, which includes not only the use of oxygen-increasing drugs but also the identification and treatment of the underlying cause of the shock, fluid resuscitation, and other supportive measures. Oxygen-increasing drugs should be utilized as adjunctive therapies in conjunction with these standard interventions.

Moreover, it is crucial to consider the potential side effects and contraindications associated with these medications. Vasopressors and inotropes, for example, can have adverse effects on cardiac function and blood pressure regulation if not appropriately administered. Oxygen therapies, when used at high concentrations for extended periods, may increase the risk of oxygen toxicity. Hyperbaric oxygen therapy requires specialized facilities and careful monitoring due to the risk of barotrauma and other complications. Perfluorocarbon emulsions are still under investigation and their long-term effects and safety profile are not yet fully established.

In conclusion, the utilization of drugs to enhance oxygen uptake in end organs during hypovolemic shock is an area of active research and clinical exploration. While several medications and therapies show promise in optimizing tissue oxygenation, their efficacy and safety must be thoroughly investigated through rigorous studies and trials. It is vital for healthcare professionals to stay up to date with the latest evidence and guidelines to ensure the appropriate and judicious use of these interventions. By combining these oxygen-increasing drugs with established resuscitation strategies, medical professionals can strive to improve outcomes for patients with hypovolemic shock and enhance their chances of a successful recovery.

Ethics Statement

(1) All the authors mentioned in the manuscript have agreed to authorship, read and approved the manuscript, and given consent for submission and subsequent publication of the manuscript.
(2) The authors declare that they have read and abided by the JEVTM statement of ethical standards including rules of informed consent and ethical committee approval as stated in the article.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

REFERENCES

[1] Li H, Li Y, Fu Y, Zhang X, Zhang D. The intensity of organ support: restrictive or aggressive therapy for critically ill patients. J Intensive Med. 2023;3(4):298–302.
[2] Paxian M, Keller SA, Huynh TT, Clemens MG. Perflubron emulsion improves hepatic microvascular integrity and mitochondrial redox state after hemorrhagic shock. Shock. 2003;20(5):449–57.
[3] Bialas C, Moser C, Sims CA. Artificial oxygen carriers and red blood cell substitutes: a historic overview and recent developments toward military and clinical relevance. J Trauma Acute Care Surg. July 2019;87(1S Suppl 1):S48–S58.
[4] Torres Filho IP. Mini-review: perfluorocarbons, oxygen transport, and microcirculation in low flow states: in vivo and in vitro studies. Shock. October 2019;52(1S Suppl 1):19–27.